Rabies – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Rabies – Pipeline Review, H1 2020’, provides an overview of the Rabies pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rabies and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Rabies

– The report reviews pipeline therapeutics for Rabies by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rabies therapeutics and enlists all their major and minor projects

– The report assesses Rabies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rabies

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rabies

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Cadila Healthcare Ltd

Changchun Bcht Biotechnology Co Ltd

Chengdu Rongsheng Pharmaceutical Co Ltd

Chongqing Zhifei Biological Products Co Ltd

CPL Biologicals Pvt Ltd

Curevac AG

GlaxoSmithKline Plc

Humabs BioMed SA

Indian Immunologicals Ltd

Mid-Atlantic BioTherapeutics, Inc.

Molecular Targeting Technologies Inc

NanoViricides Inc

Sanofi

Shandong Yidu Biotechnology Co Ltd

Shanghai Qingsai Biotechnology Co Ltd

Synermore Biologics Co Ltd

Trellis Bioscience Inc

Univercells SA

Yisheng Biopharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rabies - Overview

Rabies - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rabies - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rabies - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cadila Healthcare Ltd

Changchun Bcht Biotechnology Co Ltd

Chengdu Rongsheng Pharmaceutical Co Ltd

Chongqing Zhifei Biological Products Co Ltd

CPL Biologicals Pvt Ltd

Curevac AG

GlaxoSmithKline Plc

Humabs BioMed SA

Indian Immunologicals Ltd

Mid-Atlantic BioTherapeutics, Inc.

Molecular Targeting Technologies Inc

NanoViricides Inc

Sanofi

Shandong Yidu Biotechnology Co Ltd

Shanghai Qingsai Biotechnology Co Ltd

Synermore Biologics Co Ltd

Trellis Bioscience Inc

Univercells SA

Yisheng Biopharma Co Ltd

Rabies - Drug Profiles

(Lassa fever + rabies) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNSP-333S1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-7202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-8102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3903133A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nadorameran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Niprab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RabiCide-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-58 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SO-57 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOJB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VerorabVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VRVg-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rabies - Dormant Projects

Rabies - Product Development Milestones

Featured News & Press Releases

Jan 07, 2020: CureVac announces positive results in low dose - 1 µg - Rabies vaccine clinical phase 1 study

Sep 03, 2019: Zydus to launch novel biologic for rabies, Twinrab

Jul 22, 2019: Yisheng Biopharma receives GMP certification from China NMPA for production of lyophilized rabies vaccine for preventive use

Oct 23, 2018: CureVac announces first study participant enrolled in Phase I clinical trial testing prophylactic mRNA

Oct 08, 2018: Yisheng Biopharma announces clearance from China FDA to proceed with PIKA rabies vaccine clinical study

Jul 26, 2017: CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Jun 30, 2017: SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study

Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference

Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine

Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

Jul 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study

May 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study

Apr 30, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study

Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies

Mar 16, 2015: A new therapeutic vaccine successfully developed against rabies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rabies, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Rabies – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020

Rabies – Pipeline by Cadila Healthcare Ltd, H1 2020

Rabies – Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020

Rabies – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020

Rabies – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020

Rabies – Pipeline by CPL Biologicals Pvt Ltd, H1 2020

Rabies – Pipeline by Curevac AG, H1 2020

Rabies – Pipeline by GlaxoSmithKline Plc, H1 2020

Rabies – Pipeline by Humabs BioMed SA, H1 2020

Rabies – Pipeline by Indian Immunologicals Ltd, H1 2020

Rabies – Pipeline by Mid-Atlantic BioTherapeutics, Inc., H1 2020

Rabies – Pipeline by Molecular Targeting Technologies Inc, H1 2020

Rabies – Pipeline by NanoViricides Inc, H1 2020

Rabies – Pipeline by Sanofi, H1 2020

Rabies – Pipeline by Shandong Yidu Biotechnology Co Ltd, H1 2020

Rabies – Pipeline by Shanghai Qingsai Biotechnology Co Ltd, H1 2020

Rabies – Pipeline by Synermore Biologics Co Ltd, H1 2020

Rabies – Pipeline by Trellis Bioscience Inc, H1 2020

Rabies – Pipeline by Univercells SA, H1 2020

Rabies – Pipeline by Yisheng Biopharma Co Ltd, H1 2020

Rabies – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Rabies, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports